What is inconsistent with the results in the TCGA database regarding the impact of CFAP65 on the prognosis of colon cancer is that our results indicate there was a significant difference in 5-year DFS between the CFAP65 high- and the low-expression groups (72.6% vs. 56.9%, P = 0.03) (Fig. 6a), suggesting high expression of CFAP65 predicts better prognosis, and the 5-years OS rate has no significant difference between high- and low-expression groups (78.6% vs. 69%, P = 0.171) (Fig. 6b). Here, CFAP65 is linked to malignant colon neoplasm.